{
    "id": "8fcd9ba1-e742-4ed6-9fd0-3a790da34bf8",
    "indications": "carefully consider potential benefits risks nabumetone tablets treatment options deciding nabumetone tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . nabumetone tablets indicated relief signs symptoms osteoarthritis rheumatoid arthritis .",
    "contraindications": "carefully consider potential benefits risks nabumetone tablets treatment options deciding nabumetone tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy nabumetone tablets , dose frequency adjusted suit individual patient 's needs .",
    "warningsAndPrecautions": "nabumetone tablets usp , 500 mg white , oval-shaped , film-coated , biconvex tablets debossed “ 3670 ” one side tablet plain side . available bottles 100 500. ndc 0591-3670-01. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles 100 ndc 0591-3670-05. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles 500 nabumetone tablets usp , 750 mg pink , oval-shaped , film-coated , biconvex tablets debossed “ 3671 ” one side tablet plain side . available bottles 100 500. ndc 0591-3671-01. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles 100 ndc 0591-3671-05. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . bottles 500 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . dispense medication guide available : www.tevausa.com/medguides manufactured india : watson pharma private ltd. verna , salcette goa 403 722 india manufactured : teva pharmaceuticals parsippany , nj 07054 rev . f 10/2024",
    "adverseReactions": "nabumetone tablets contraindicated patients known hypersensitivity nabumetone product excipients . nabumetone tablets given patients experienced asthma , urticaria , allergic-type taking aspirin nsaids . severe , rarely fatal , anaphylactic-like nsaids reported patients ( , anaphylactoid , general , preexisting asthma ) . • setting coronary artery bypass graft ( cabg ) surgery [ ] .",
    "ingredients": [
        {
            "name": "NABUMETONE",
            "code": "LW0TIW155Z"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "organization": "Actavis Pharma, Inc.",
    "name": "Nabumetone",
    "effectiveTime": "20241007",
    "indications_original": "Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS\n                     ).\n\n                  Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.",
    "contraindications_original": "Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS\n                     ).\n\n                  After observing the response to initial therapy with nabumetone tablets, the dose and frequency should be adjusted to suit an individual patient's needs.",
    "warningsAndPrecautions_original": "Nabumetone tablets USP, 500 mg are white, oval-shaped, film-coated, biconvex tablets debossed with “3670” on one side of the tablet and plain on the other side. They are available in bottles of 100 and 500.\n                  NDC 0591-3670-01...............................bottles of 100\nNDC 0591-3670-05...............................bottles of 500\n                  Nabumetone tablets USP, 750 mg are pink, oval-shaped, film-coated, biconvex tablets debossed with “3671” on one side of the tablet and plain on the other side. They are available in bottles of 100 and 500.\n                  NDC 0591-3671-01...............................bottles of 100\nNDC 0591-3671-05...............................bottles of 500\n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. \n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Dispense with Medication Guide available at: www.tevausa.com/medguides\n                  Manufactured In India By:\n                     Watson Pharma Private Ltd.\n                     \nVerna, Salcette Goa 403 722 INDIA\n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     Parsippany, NJ 07054\n                  Rev. F 10/2024",
    "adverseReactions_original": "Nabumetone tablets are contraindicated in patients with known hypersensitivity to nabumetone or product excipients.\n\n                  Nabumetone tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see \n                        WARNINGS\n                     \n                     ,\n                     \n                         Anaphylactoid Reactions\n                      and \n                        PRECAUTIONS\n                     \n                     ,\n                     \n                         General\n                     \n                     , \n                     Preexisting Asthma).\n\n                  • In the setting of coronary artery bypass graft (CABG) surgery [see \n                        Warnings\n                     ]."
}